Drug Discovery World

JANUARY 20, 2023

Precision medicine uses information about an individual’s genes, proteins, and environment to prevent, diagnose, and treat diseases, including cancer. Differences in DNA, RNA, and protein can be identified in individual tissue samples, and even in individual cells.

Medicine 52

Medicine Genotype Protein RNA 52

Delveinsight

DECEMBER 13, 2020

This discovery led to the development of diagnostic tests and an effective vaccine, and Blumberg was awarded the Nobel Prize in Physiology or Medicine in 1976 for this discovery. The first approved treatment for hepatitis C was a series of protein-based injections called recombinant interferon-alfa (IFNa). Hepatitis Treatment pattern.

Genotype 52

Genotype FDA Approval DNA Drugs 52

The Pharma Data

OCTOBER 9, 2021

Food and Drug Administration (FDA) Antimicrobial Drugs Advisory Committee (AMDAC) voted unanimously to recommend use of maribavir (TAK-620) for the treatment of refractory cytomegalovirus (CMV) infection and disease with genotypic resistance to ganciclovir, valganciclovir, foscarnet or cidofovir in transplant recipients.

Drugs 52

Drugs Genotype Bioavailability Medicine 52

The Pharma Data

MARCH 16, 2022

TIB Molbiol offers a broad range of VirSNiP variant test kits for the detection of key spike protein mutations. The company launched eight RUO VirSNiP test kits for use on LightCycler® and cobas z 480 analyzers, for the detection of key spike protein mutations present in the novel B.1.1.529 1.1.529 Omicron SARS-CoV-2 variant.

In-Vitro 52

In-Vitro Genotype Reagent Protein 52

The Pharma Data

DECEMBER 9, 2020

Vigil’s pipeline strategy is to target these diseases by combining a high-level understanding of microglia physiology, disease genotyping, and patient phenotyping to identify specific genetic variations associated with microglial dysfunction. Li is a prominent neuroscientist and former professor at Johns Hopkins Medicine.

Marketing 52

Marketing In-Vivo Protein In-Vitro 52

The Pharma Data

MARCH 25, 2021

SG is a first-in-class therapy targeting Trop-2, a protein frequently expressed in multiple types of epithelial tumors, such as TNBC, where high expression is associated with poor survival and relapse. Canada, Switzerland and Australia, as well as in Singapore through our partner Everest Medicines. Gilead Sciences, Inc.

Genotoxicity 52

Genotoxicity Genotype Containment Protein 52

Drug Discovery World

DECEMBER 12, 2023

Korro’s RNA editing approach has the potential to be transformative for AATD patients and Korro is well-positioned to deliver a best-in-class therapeutic.

RNA 52

RNA In-Vivo Genotype Genetics 52